Loading…
Loading…
ELAN does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ELAN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ELAN and 80,000+ other tickers.
See exactly how ELAN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ELAN and 80,000+ other tickers.
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and…
The purchase was valued at $936,000. This investment increased the insider's direct equity position by 27%.
Canada Pension Plan Investment Board purchased a new position in Elanco Animal Health Incorporated (NYSE: ELAN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 51,700 shares of the company's stock, valued at approximately $1,272,000. Several other hedge funds and other institutional investors also
Corient Private Wealth LP purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE: ELAN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 348,043 shares of the company's stock, valued at approximately $8,565,000. Corient Private Wealth LP owned approximately
Corient Private Wealth LP raised its stake in Elanco Animal Health Incorporated (NYSE: ELAN) by 127.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 348,043 shares of the company's stock after acquiring an additional 195,312 shares during the
Algert Global LLC trimmed its holdings in Elanco Animal Health Incorporated (NYSE: ELAN) by 19.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 180,430 shares of the company's stock after selling 42,410 shares during the quarter. Algert Global LLC's holdings